Search

Your search keyword '"Tripathi, N."' showing total 727 results

Search Constraints

Start Over You searched for: Author "Tripathi, N." Remove constraint Author: "Tripathi, N."
727 results on '"Tripathi, N."'

Search Results

10. Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma

11. Chemical Composition, Antioxidant, and Antifungal Characteristics of the Essential oil of Mansoa alliacea (Lam.) A.H. Gentry.

21. Predicting Land Use and Land Cover Changes in Pathumthani, Thailand: A Comprehensive Analysis from 2013 to 2023 Using Landsat Satellite Imagery and CAANN Algorithm, with Projections for 2028 and 2038.

31. 1399P Androgen receptor (AR) alterations on circulating tumor DNA (ctDNA) sequencing and response to the first-line androgen-receptor targeted agent (ARAT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

32. 1413P Tumor transcriptomic profiling of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) who do not achieve optimal PSA response to intensified androgen deprivation therapy (ADT-I)

33. 1373P SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC)

35. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019

37. ULF Wave-Associated Density Irregularities and Scintillation at the Equator

44. Effect of Biomass Burning on PM2.5 Composition and Secondary Aerosol Formation During Post‐Monsoon and Winter Haze Episodes in Delhi

48. 1899P Comparative effectiveness of second-line (2L) treatment (Rx) with cabozantinib (cabo) in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after first-line (1L) Rx with ipilimumab + nivolumab (ipi+nivo) vs. PD-1/L1 inhibitor (PDI) + tyrosine kinase inhibitor (TKI)

49. 1898P Comparative real-world effectiveness of PD-1/L1 inhibitor (PD-1i) plus cabozantinib (cabo) vs cabo after progression with prior immune checkpoint inhibitor (ICI) treatment (Rx) in metastatic clear cell renal cell carcinoma (mccRCC)

50. 2380P Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

Catalog

Books, media, physical & digital resources